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Short-Term Administration of Rifampin in the Prevention or Eradication
of Infection Due to Foreign Bodies
K. Tshefu, w. Zimmerli, and F. A. Waldvogel From the Infectious Disease Division,
Department of Medicine, University Hospital,
Geneva, Switzerland
Short-term administration of rifampin was evaluated as a means of preventing or eradi-
cating infection due to foreign bodies. Tissue cages were implanted into guinea pigs and
subsequently infected with 103 colony-forming units of Staphylococcus aureus Wood
46. Infection developed in all tissue cages. Rifampin was administered thereafter in-
traperitoneally at a dosage of 7.5 mg/kg every 12 hr for 48 hr, and the tissue-cage fluid
was monitored for possible development of infection by quantitative bacteriologic
methods for 15 days. In all cases rifampin prevented or eradicated tissue-cage infection
if treatment was initiated either 3 hr before or ~12 hr after inoculation of microorga-
nisms but was ineffective if initiated >12 hr after inoculation. In cases of failure of
treatment, rifampin-resistant variants could be demonstrated. Rifampin seems to pre-
vent or eradicate tissue-cage infection only if given early after bacterial inoculation.
The development of an infection in the vicinity of
a foreign body or prosthetic material remains a
major problem in orthopedic, cardiac, and general
surgery [1-3] as well as in internal medicine [4].
Conceptually, three major groups of pathogenic
factors could contribute, either singly or in com-
bination, to the development of such infections.
Altered virulence and/or surface modifications of
the infecting organisms could protect them from
host-dependent antibacterial systems or from anti-
microbial agents; alternatively, the foreign or
prosthetic surface per se could favor, either direct-
ly or indirectly, the propagation of the offending
microorganism; finally, the host's natural defense
mechanisms against pyogenic organisms might be
altered in the vicinity of a foreign body. Prelim-
inary experimental data that favor the latter two
mechanisms have recently been presented [5, 6].
Little is known about the microbiologic deter-
minants of prosthetic infections; however, the
efficacy of preventive, short-term antibiotic thera-
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py [7, 8], in contrast to the inefficacy of antibiotic
therapy initiated after infection has developed,
suggests a change in bacterial behavior during the
establishment of foreign-body infection.
Since it is generally accepted that the con-
sequences of infection in the vicinity of foreign
material are disastrous, interest is growing in the
establishment of guidelines for regimens of pre-
ventive antibiotic treatment either during insertion
of prosthetic devices or during later septic manip-
ulations. Because of the lack of an animal model,
few solid data are available about optimal dosage,
timing, and duration of such prevention programs
and the choice of antibiotics.
In the present study we used an experimental
model of foreign-body infection recently de-
veloped in our laboratory [6] to address these
questions. In particular, we evaluated the efficacy
of rifampin, an antibiotic with high antistaphy-
lococcal activity and good cell membrane penetra-
tion [9-11], in preventing or eradicating foreign-
body infection.
Materials and Methods
Experimental model. Sterile polytetrafluor-
ethylene (Teflon'") tissue cages constructed as pre-
viously described [6], with external and inter-
nal diameters of 10 mm and 8 mm, respectively,
and perforated by 130 regularly spaced holes were
implanted under strictly aseptic conditions into
the flanks of guinea pigs weighing 500-600 g.
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Animals were used for experimental infections
after the incision had healed completely and the
metal clips had been removed, i.e., two or more
weeks after surgery.
Collection and storage of tissue-cage fluid.
Samples of tissue-cage fluid were obtained by
percutaneous aspiration, which has been described
previously for a similar model [12]. Thereafter,
samples either were used directly for bacteriologic
quantitation or were stored at -70 C for further
determinations.
Microbiologic characteristics of the infecting
strain. Aliquots of the same initial culture of
Staphylococcus aureus Wood 46, stored at
-70 C, were used for all experiments. This strain
was shown by the Kirby-Bauer method [13] to be
sensitive to all common antibacterial agents
tested, including penicillin, methicillin, erythro-
mycin, tetracycline, and rifampin [14]. When sub-
mitted to a standard scheme for staphylococcal
identification, the strain gave positive reactions for
catalase production, plasma coagulase reaction,
DNase activity, and mannitol fermentation [14].
Before inoculation into tissue cages, S. aureus
Wood 46 was preincubated overnight in Mueller-
Hinton broth, centrifuged, washed, and resus-
pended in 1.0 ml of 0.85070 saline; 0.2 ml of this
diluted suspension was injected into each tissue
cage, resulting in an inoculum of 1'\)103 organisms.
Clumping of microorganisms was kept at a mini-
mum under these preincubation conditions and
was monitored regularly by microscopic evaluation.
Microorganisms isolated from infected tissue
cages were checked for their identity with the
initial, inoculated strain by the above-mentioned
biochemical tests. Appropriate antibiotic suscepti-
bility tests also were performed for confirmation
of identity between the inoculated and the isolated
microorganisms.
Microbiologic techniques. Rifampin assays
were performed with a microbiologic method in
which Sarcina lutea was used as the indicator
strain and DST (diagnostic sensitivity) Oxoid,
(Oxoid Ltd., Beckingham, England) with 3 ml of
KH2P04(IM)/100 ml was used as the medium
[15]. The assay was linear for concentrations of
rifampin of 0.12 JAg/ml-1.0 ug/ml. Pure rifampin
(Ciba-Geigy, Basel, Switzerland) was dissolved in
N, N-dimethylformamide (Sigma, St. Louis, Mo.)
at a concentration of I mg/ml. Further dilutions
were performed in PBS (Dulbecco's phosphate-
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buffered saline; Gibco-Bio-Cult., Glasgow, Scot-
land). This solution was used for the standard
curves, which were established for each assay.
Identical standard curves were obtained when PBS
was partially substituted with 25% serum or 750/0
tissue-cage fluid.
Quantitative cultures of tissue-cage fluid were
performed by plating 0.1 ml on Mueller-Hinton
agar, after making appropriate dilutions in sterile
water, and incubating cultures for 48 hr before
performing colony counts. Absence of spon-
taneous contamination of tissue-cage fluids was
confirmed before starting each experiment by cul-
turing undiluted fluid on Mueller-Hinton agar.
Finally, in some experiments tissue cages were
excised under aseptic conditions and checked for
the presence of microorganisms by rolling the
cages over Mueller-Hinton agar plates and cultur-
ing the plates subsequently in Mueller-Hinton
broth.
Results
Choice of initial inoculum and ofrifampin regi-
men. In a first series of experiments, the rate of
development of infections was quantitated by
inoculating various numbers of S. aureus Wood
46 into the tissue cages and by evaluating bacterial
multiplication as a function of time. As shown in
figure I, infection of the tissue-cage fluid was
achieved with initial inocula as small as 102 cfu
and was readily demonstrable bacteriologically by
20 hr. With an inoculum of ~103 cfu, quantitation
of bacterial counts at 22 hr showed the presence of
1'\)105-108 organisms/ml, most of them identified
as single cocci by microscopic examination. When
bacterial counts were measured after the first 24
hr, they fluctuated considerably - probably be-
cause of bacterial clumping. Finally, control
curves showed that bacterial growth in Mueller-
Hinton broth or under in vitro conditions in
tissue-cage fluid was more rapid than in the in vivo
system. These results considered together sug-
gested that 103 cfu of S. aureus Wood 46 was an
adequate initial inoculum, that an observation
period of 20 hr was sufficient for the demonstra-
tion of an infection in the absence of antibiotics,
and that fluid accumulating in tissue cages did not
provide particularly favorable growth conditions
for S. aureus Wood 46.
For evaluation of the efficacy of rifampin in ex-
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Figure 1. Growth curves of Staphylococcus aureus
Wood 46in tissue cages in vivo and control values of bac-
terial growth in either 100070 tissue-cage fluid (0; n =
3) or Mueller-Hinton broth (_; n = 3) in vitro. Indicated
inocula of S. aureus were injected into tissue cages at time
zero (arrow). Values are reported as the mean ± SEM of
the cfu at the indicated time intervals after experimental
infection with the following initial inoculum: rv102 cfu
(0----0; n = 8), rv104 cfu (e e; n = 4), rvl06
cfu (~; n = 4), rv108 (A.----A); n = 2).
perimental tissue-cage infections, an antibiotic
regimen had to be chosen that gave concentrations
of antibiotic in tissue-cage fluid exceeding the
MIC and MBC for S. aureus Wood 46. The MIC
at 18 hr in Mueller-Hinton broth was 0.005 ug/ml
with an initial inoculum of 105 cfu. The MBC,
which was defined as the antibiotic concentration
leading to a killing of 99.9070 at 24 hr, was 0.046
JJg/ml; no skip-tube phenomenon was observed.
When tests were made in Mueller-Hinton medium
supplemented with 25% pooled guinea pig serum,
MIC and MBC values were 0.023 JJg/ml and 0.046
JJg/ml, respectively. Several antibiotic regimens
were examined for the purpose of obtaining levels
of antibiotic in tissue-cage fluid exceeding the
MIC and MBC during the entire treatment period.
Figure 2 shows that with a regimen of 7.5 mg of
rifampin/kg given ip every 12 hr, trough levels of
rifampin at 24 hr and 48 hr after initation of ther-
apy were 0.115 ± 0.035 and 0.15 ± 0.027 ug/ml,
respectively, values exceeding the MIC for S. aureus
Wood 46 by factors of 5 and 6.5, respectively.
Partial prevention or eradication of infections
of tissue-cage fluid with rifampin: emergence of
rifampin-resistant mutants. Seven different treat-
ment schedules (A-G; table 1) were evaluated;
they differed by one parameter only-i.e., the
time lag between the inoculation of the micro-
organisms and the initiation of therapy. This time
lag varied from - 3 hr (for treatment group A;
antibiotic regimen started 3 hr before inoculation)
to 48 hr (for group G; antibiotic regimen started
48 hr after inoculation). Tissue-cage fluids of
groups A-F were aspirated and cultured 24 hr, 48
hr, six days, and 15 days after initiation of
therapy.
In group G the establishment of infection was
confirmed 24 hr before and at the beginning of rif-
Administration of Rifampin
Figure 2. Trough level of rifampin
(J.lg/ml) in tissue-cage fluid 24 hr and
48 hr after administration of 7.5 mg
of rifampin/kg ip every 12 hr for 48
hr. The solid line represents the MIC
and the dotted line, the MBC of the
infecting strain, Staphylococcus au-
reus Wood 46.
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Table 1. Treatment regimens for guinea pigs with
foreign-body infections.
NOTE. Tissue-cage fluid was sampled for quantitative
cultures at 24 hr, 48 hr, six days, and 15 days after the onset of
the antibiotic prophylaxis or therapy.
* Tissue cages were inoculated with 103 cfu of Staphylo-
coccus aureus Wood 46. Dosage of rifampin was 7.5 mg/kg ip
every 12 hr for 48 hr.
ampin treatment. Further cultures of tissue-cage
fluid were performed at 24 hr, six days, nine days,
and 15 days after initiation of therapy. Results of
these experiments are described in tables 1 and 2.
When rifampin was administered either before,
during, or 12 hr after inoculation of S. aureus
Wood 46, tissue cages were invariably sterile when
tested six days or 15 days after initiation of the
48-hr treatment regimen. Eradication of infection
was achieved at the end of therapy, even in cases
for which tissue-cage fluids were culture positive
at 48 hr, i.e., contained up to 103 cfu/ml. If initia-
tion of therapy was delayed beyond 12 hr after
inoculation, infection could not be eradicated;
Prophylaxis or
treatment group
A
B
C
D
E
F
G
Rifampin administered
at indicated interval (hr) No. of tissue
before ( - ) or after ( + ) cages
inoculation inoculated*
-3 7
o 8
+3 10
+6 8
+ 12 8
+24 8
+48 4
despite the fact that tissue-cage fluids were nega-
tive six days after initiation of the 48-hr therapy,
eight of 11 were positive at 15 days, with bacterial
counts ranging from 102 to 108 cfu/ml. It is of in-
terest that after administration of antibiotic infec-
tion in the tissue-cage fluid recurred slowly, re-
quiring observation periods of up to 15 days for
confirmation of all relapses. These results were in
striking contrast with those obtained in the ab-
sence of the antibiotic, for which bacterial growth
could consistently be demonstrated in tissue-cage
fluid 12 hr after inoculation.
Because of the delay in recurrence of infection,
we investigated whether negative cultures actually
reflected the inadequacy of the technique of aspir-
ating tissue-cage fluid for collecting bacteria close-
ly associated with the foreign body. Tissue cages
with sterile fluid cultures were therefore excised 15
days after initiation of effective rifampin treat-
ment and cultured according to the technique de-
scribed in Materials and Methods; all cages were
free of organisms. In one case of ineffective treat-
ment - rifampin was started 48 hr after inocula-
tion of S. aureus (group G)-tissue-cage fluid was
negative at 15days, whereas the excised tissue cage
showed growth with both techniques (table 2 and
figure 3).
The time course of the recurrence of infection is
depicted in more detail in figure 3 for four tissue
cages in animals in which rifampin treatment was
started 48 hr after inoculation of bacteria. Bac-
terial counts decreased from initial values of 2.5
x 104-1.6 x 10648 hr after inoculation to <10 cfu
Table 2. Effect of time of initiation of rifampin regimen on protection against or eradication of foreign-body
infection.
Treatment group, no. of hr
before (-) or after (+) inoculation
that rifampin regimen initiated*
A, -3
B,O
C, +3
D, +6
E, +12
F, +24
G, +48
No. of tissue-cage fluids positive for infecting organism on indicated day
after initiation of rifampin/no. inoculatedf
2 6 15
0/7 1/7 (101-102) 0/7 ND
0/4 0/4 0/4 Ol4t
0110 0110 0110 ND
4/8 (101-103) 4/8 (101-103) 0/8 ND
6/8 (101-103) 0/16 0/16 0/8t
5/8 (102-104 ) 11/15 (101-108) 0/15 4/7 (108)
4/4 (103-105) ND 0/4 4/4 (101-l06)§
* Tissue cages were inoculated with 103 cfu of Staphylococcus aureus Wood 46. Dosage of rifampin was 7.5 mg/kg ip every
12 hr for 48 hr.
t Numbers in parentheses are cfu/ml of tissue-cage fluid. ND = not done.
t All excised tissue cages also were culture negative.
§ In one case only the tissue cage was culture positive.
CULTURE OF ASPIRATED TISSUE CAGE (TC) FLUID
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Figure 3. Number of cfu of Staphylococcus aureus Wood 46 in tissue-cagefluid in four guinea pigs treated according to
treatment regimen G and susceptibility of isolates to rifampin at end of observation period. Time zero indicates initiation
of therapy with 7.5 mg of rifampin/kg ip every 12 hr for 48 hr. Tissue cages were excised 15 days after initiation
of therapy and cultured in Mueller-Hinton broth (for details see Materials and Methods); all four cages were positive
for S. aureus Wood 46 (at right).
six days after initiation of the 48-hr therapy regi-
men. Bacterial counts in tissue-cage fluid gradual-
ly increased at nine days for two of four cages and
at 15 days for three of four cages. The fourth
tissue-cage fluid was negative throughout the ob-
servation period, whereas all excised tissue cages
were positive. Finally, one of four cultures ob-
tained at the end of the observation period showed
two types of S. aureus, one that remained sensitive
to 0.023 Ilg of rifampin/rnl, the other that was re-
sistant to >31 lAg of rifampin/ml. Both types of
S. aureus colonies were identical in all other bio-
chemical characteristics and antibiotic sensitivities.
Discussion
Despite the abundant use of antibacterial agents
for the prevention of postsurgical infections, there
is no general consensus as to their indications,
choice, timing, and duration of administration
[16]. This lack of adequate guidelines is of even
greater concern for those infections that occur
after insertion of prosthetic material, since such
infections are associated with a particularly poor
prognosis. Prosthetic valve endocarditis and
osteomyelitis following reconstructive orthopedic
surgery usually require the removal of the foreign
material for cure [1, 17]. It therefore seems partic-
ularly desirable to establish appropriate antibiotic
regimens for the prevention or early eradication of
these infections, which most often are due to
staphylococci.
The paucity of clinical data regarding prosthetic
infections and their prevention probably reflects
the difficulty in setting up adequate controlled
studies, which require unambiguous criteria for
the assessment of infection, accurate determina-
tions of antibiotic concentrations in the neighbor-
hood of the prosthesis, and well-defined end
points for both duration of antibiotic therapy and
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the consecutive observation periods. We believe
that the present experimental model, which has
previously been used for pharmacokinetic stud-
ies [12, 18] and for establishment of successful
growth of fastidious microorganisms [19], can be
applied to answer some of these questions.
Our results show that administration of rifam-
pin at a dosage regimen that achieves bactericidal
concentrations in tissue-cage fluid for at least 48
hr prevented the development of foreign-body in-
fection, provided that antibacterial treatment was
started ~ 12 hr after inoculation of a rifampin-
sensitive strain of S. aureus. If the time lag be-
tween the inoculation of the pathogen and the
initiation of therapy was>12 hr, however, infec-
tion invariably developed despite treatment with
rifampin for 48 hr, and occasionally rifampin-
resistant variants emerged. Finally, whereas tis-
sue-cage infections developed in <20 hr in the
absence of rifampin administration, more than six
days were required for them to be detected micro-
biologically after unsuccessful rifampin therapy.
This observation could be explained by a pro-
longed postantibiotic effect, as described for other
antibacterial agents [20]. Alternatively, persistent
bacteria may have remained adherent to the for-
eign body and protected from the antibiotic effect,
contaminating the tissue-cage fluid at a later stage.
Finally, some rifampin-resistant mutants of S. au-
reus Wood 46 produce less catalase and are
less pathogenic than the wild strain in mice [21]. In
our experience, however, both the resistant and
the sensitive variants were equally susceptible to
the bactericidal action of peritoneal granulocytes.
Present work in our laboratory is aimed at the
further evaluation of these possibilities.
The experimental system presented in this com-
munication requires two comments. First, despite
others' claims to having encountered difficulty in
performing bactericidal assays with S. aureus
Wood 46 [22], we did not encounter any such
problems; the MIC and MBC were in the range of
those given by Mandell for the same organism [10]
and by others for various strains of S. aureus [9,
23]. Second, we occasionally observed delayed in-
fection of tissue-cage fluid or infection limited to
the tissue cage after ineffective rifampin treat-
ment. These observations could suggest that in the
case of "effective" rifampin treatment cultures of
tissue-cage fluid were falsely negative because
either the observation period was too short or
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microorganisms persisted on the Teflon'" surface.
These possibilities were ruled out by control ex-
periments involving the excision of tissue cages
with culture-negative fluid and the demonstration
of the sterility of the cages by adequate culture
techniques.
The incomplete protection or eradication of
infection demonstrated with short-term adminis-
tration of rifampin in our experimental model is in
keeping with similar data obtained with experi-
mental endocarditis [24], osteomyelitis [25], and
peritonitis [26]. In all four conditions, high num-
bers of bacteria were exposed to rifampin, either
because of a prolonged delay between inoculation
and initiation of antibacterial therapy (our study
and [24, 25]) or because of a high initial inoculum
[26]. It is therefore not surprising that in all four
experimental conditions, emergence of rifampin-
resistant variants was demonstrated. This observa-
tion obtained in different experimental models
might well set a limit on the use of rifampin as a
single therapeutic agent - but not necessarily as a
prophylactic drug - since initial inocula probably
are low in clinical postsurgical infections.
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